GlassScriptPhysician profile
Olga Leonardi
NPI 1982666004
$10,487.35
in general payments reported to CMS, 2019-2025
38 companies · $2,546 in 2025
The $2,546 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,297 · 2020: $726 · 2021: $665 · 2022: $1,124 · 2023: $1,503 · 2024: $2,626 · 2025: $2,546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,591 · Education: $83.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,590.60 |
| Education | $83.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,672.42 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $2,102.51 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $524.63 | 2019-2024 | |
| Abbott Laboratories | $512.35 | 2020-2025 | Freestyle Libre 3 |
| Alexion Pharmaceuticals, INC. | $477.57 | 2024-2025 | Strensiq |
| Astrazeneca Pharmaceuticals LP | $456.52 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $423.71 | 2019-2025 | Jardiance |
| Amgen INC. | $376.27 | 2023-2025 | Tepezza, Evenity, Repatha |
| Radius Health, INC. | $358.56 | 2019-2025 | Tymlos, Binosto |
| Abbvie INC. | $324.00 | 2019-2025 | |
| Mannkind Corporation | $266.56 | 2019-2025 | Afrezza |
| Insulet Corporation | $188.17 | 2019-2025 | Omnipod |
| Pfizer INC. | $182.21 | 2022-2025 | |
| Ibsa Pharma INC. | $179.49 | 2021-2024 | Tirosint, Licart, Tirosint |
| Sequel Med Tech, LLC | $171.78 | 2025 | Twiist |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $130.10 | 2022-2025 | Unithroid |
| Merck Sharp & Dohme LLC | $120.36 | 2019-2021 | |
| Antares Pharma, INC. | $108.16 | 2022-2025 | Xyosted |
| Acella Pharmaceuticals, LLC | $86.81 | 2023-2025 | NP Thyroid 60 |
| Medtronic, INC. | $79.43 | 2021-2025 | Minimed 780g |
| Corcept Therapeutics | $78.82 | 2025 | Korlym |
| Dexcom, INC. | $75.51 | 2021-2023 | Dexcom G6 Transmitter |
| Aytu Biopharma, INC. | $65.17 | 2019 | |
| Currax Pharmaceuticals LLC | $64.92 | 2022-2025 | Contrave |
| Bayer Healthcare Pharmaceuticals INC. | $61.51 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $60.89 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Novartis Pharmaceuticals Corporation | $52.75 | 2024 | |
| Recordati_rare_diseases_inc. | $52.42 | 2025 | Isturisa |
| Vivus LLC | $45.39 | 2021-2022 | |
| Medtronic Minimed, INC. | $30.92 | 2019 | |
| Acerus Pharmaceuticals Corporation | $26.77 | 2020-2021 | |
| Intra-Sana Laboratories | $23.21 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Rgh Enterprises LLC | $22.55 | 2024 | |
| Embecta Corp. | $22.21 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Horizon Therapeutics Plc | $18.19 | 2023 | Tepezza |
| Eisai INC. | $16.09 | 2019 | |
| Madrigal Pharmaceuticals | $14.95 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Leonardi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.